Has Lawrence Singerman, MD received payments from drug or device companies?

Yes. Drug and device makers reported $599,310 in general payments to Lawrence Singerman, MD across 164 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Lawrence Singerman, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Lawrence Singerman, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Lawrence Singerman, MD

Ophthalmology · Beachwood, OHNPI 1780678029

Payments from drug & device makers

What this record shows

This record is dominated by other: $450,676 of the $599,310 with a category attached, or 75.2%. US Retina LLC accounts for 99.2% of it on its own, with 16 other manufacturers making up the rest. Reporting peaked in 2021 at $431,713 and has fallen 99.8% since, to $815 in 2025. Among ophthalmology clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$599,310in general payments, 2019–2025

Across 164 payments — averaging $3654.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

US Retina LLC$595K
Regeneron Healthcare Solutions, Inc.$1K
Genentech USA, Inc.$779
AbbVie$737
Alimera Sciences, Inc.$590
Apellis Pharmaceuticals, Inc.$423
plus $1K from 11 others

$3,306,085in research payments, 2019–2025

Across 587 payments — averaging $5632.17 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Genentech, Inc.$896K
Regeneron$847K
Apellis Pharmaceuticals, Inc.$779K
Novartis$778K
AbbVie$3K
F. Hoffmann-la Roche AG$2K

What the payments were for

Speaking & faculty fees$2090%
Food & beverage$4,5401%
Ownership interest$143,88424%
Other$450,67675%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
US Retina LLC	12	$594,534
Regeneron Healthcare Solutions, Inc.	49	$1,163
Genentech USA, Inc.	30	$779
AbbVie(2 entities)	18	$737
Alimera Sciences, Inc.	16	$590
Apellis Pharmaceuticals, Inc.	16	$423
Notal Vision, Inc.	1	$209
Genentech, Inc.	2	$156
Novartis	4	$153
Bausch & Lomb Americas Inc.	3	$142
Coherus Oncology, Inc.	1	$135
Astellas Pharma US Inc	5	$130
Sandoz	2	$55
ANI Pharmaceuticals, Inc.	2	$36
Baxter Healthcare	1	$27
Eyepoint US, Inc.	1	$23
Bausch & Lomb, A Division Of Bausch Health US, LLC	1	$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$599,310 in reported general payments places this provider in the 95th percentile of 640 ophthalmology providers in Ohio.

See all ophthalmology providers in Ohio →

Medicare billing

Part B allowed, 2024

$2,491,244

Medicare patients

542

Services billed

18,799

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Prednisolone Acetate	59	$2,054
Brimonidine Tartrate	18	$2,032
Ketorolac Tromethamine	48	$1,302
Latanoprost	29	$359
Timolol Maleate	39	$314
Ofloxacin	15	$142

Paid to pharmacies, not to this prescriber.

Other ophthalmology in Beachwood

Hang PhamBeachwood$10K
Peter KaiserCleveland$1.5M
Gregory EippertMentor$813K
Robert OsherCincinnati$720K
Justis EhlersCleveland$639K
Darrell WhiteWestlake$587K
Alice EpitropoulosColumbus$531K
Amy MillerDayton$526K
Sunil SrivastavaCleveland$508K
William WileyCleveland$479K

See the full list for Ohio →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →